JP2019527729A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527729A5
JP2019527729A5 JP2019522614A JP2019522614A JP2019527729A5 JP 2019527729 A5 JP2019527729 A5 JP 2019527729A5 JP 2019522614 A JP2019522614 A JP 2019522614A JP 2019522614 A JP2019522614 A JP 2019522614A JP 2019527729 A5 JP2019527729 A5 JP 2019527729A5
Authority
JP
Japan
Prior art keywords
formulation
polypropylene glycol
therapeutic
ppm
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527729A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/041691 external-priority patent/WO2018013673A1/en
Publication of JP2019527729A publication Critical patent/JP2019527729A/ja
Publication of JP2019527729A5 publication Critical patent/JP2019527729A5/ja
Pending legal-status Critical Current

Links

JP2019522614A 2016-07-13 2017-07-12 治療用タンパク質製剤のための安定化賦形剤 Pending JP2019527729A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662361793P 2016-07-13 2016-07-13
US62/361,793 2016-07-13
PCT/US2017/041691 WO2018013673A1 (en) 2016-07-13 2017-07-12 Stabilizing excipients for therapeutic protein formulations

Publications (2)

Publication Number Publication Date
JP2019527729A JP2019527729A (ja) 2019-10-03
JP2019527729A5 true JP2019527729A5 (OSRAM) 2020-08-06

Family

ID=60941865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522614A Pending JP2019527729A (ja) 2016-07-13 2017-07-12 治療用タンパク質製剤のための安定化賦形剤

Country Status (6)

Country Link
US (4) US10279048B2 (OSRAM)
EP (1) EP3484520A4 (OSRAM)
JP (1) JP2019527729A (OSRAM)
KR (1) KR20190027878A (OSRAM)
CA (1) CA3030422C (OSRAM)
WO (1) WO2018013673A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2019036619A1 (en) * 2017-08-18 2019-02-21 Reform Biologics, Llc STABILIZING EXCIPIENTS FOR FORMULATIONS OF THERAPEUTIC PROTEIN
EP3761962A4 (en) * 2018-03-07 2021-12-15 ReForm Biologics, Inc. EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS
US11318183B2 (en) 2018-03-20 2022-05-03 Mankind Pharma Ltd. Stable pharmaceutical composition of vasopressin
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
WO2020061416A1 (en) 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Carbetocin drug product and process for preparing same
US20200093884A1 (en) 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
KR102771126B1 (ko) 2019-04-19 2025-02-20 후지필름 가부시키가이샤 세포 외 소포의 보존 안정화제 및 보존 안정화 방법
JP2023532764A (ja) * 2020-07-07 2023-07-31 エフ． ホフマン－ラ ロシュ アーゲー 治療用タンパク質製剤の安定剤としての代替界面活性剤
CN119403545A (zh) * 2022-04-22 2025-02-07 爱尔兰詹森科学公司 冷冻干燥的组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2510633C3 (de) 1975-03-12 1978-07-13 Boehringer Mannheim Gmbh, 6800 Mannheim Diagnostisches Mittel zum Nachweis von Eiweiß in Körperflüssigkeiten und dafür geeignete Indikatorfarbstoffe
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US6039977A (en) * 1997-12-09 2000-03-21 Alza Corporation Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods
DE60211494T2 (de) * 2001-03-26 2006-10-12 Novartis Ag Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer
US7041088B2 (en) 2002-10-11 2006-05-09 Ethicon, Inc. Medical devices having durable and lubricious polymeric coating
DE10325198B4 (de) 2003-06-04 2007-10-25 Clariant Produkte (Deutschland) Gmbh Verwendung von alkoxylierten vernetzten Polyglycerinen als biologisch abbaubare Emulsionsspalter
US8025915B2 (en) 2006-01-11 2011-09-27 Schott Ag Method of preparing a macromolecule deterrent surface on a pharmaceutical package
ES2543735T3 (es) 2007-10-22 2015-08-21 Becton Dickinson And Company Artículos médicos revestidos con organopolisiloxano que contienen una disolución de proteína y un tensioactivo no iónico
WO2009065126A2 (en) * 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
SG178193A1 (en) * 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
RU2588658C2 (ru) * 2010-04-27 2016-07-10 ЭсСиАйЭл Текнолоджи ГмбХ Стабильные водные композиции белка mia/cd-rap
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
EP2688910B1 (en) * 2011-03-25 2019-05-29 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
JP2015519361A (ja) 2012-05-31 2015-07-09 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 正電荷有機添加剤での処理によるタンパク質製剤におけるタンパク質−不純物複合体及び凝集体のレベルを低下させるための方法
CA2881818A1 (en) * 2012-08-21 2014-02-27 Genesys Research Institute Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9474803B2 (en) 2012-11-27 2016-10-25 Alteogen Inc. Composition for stabilizing fusion protein in which protein and FC domain are fused
WO2014151705A1 (en) 2013-03-15 2014-09-25 Ansun Biopharma, Inc. Methods for preparing injectable protein microparticle suspensions
KR20150144804A (ko) * 2013-04-22 2015-12-28 글리코토페 게엠베하 낮은 푸코실화를 갖는 항­ｅｇｆｒ 항체를 이용한 항암 치료
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations

Similar Documents

Publication Publication Date Title
EP2525787B1 (en) Liquid formulations for long-acting g-csf conjugate
EP2914246B1 (en) Stabilizer for hyaluronidase and liquid formulation comprising hyaluronidase
Rajoria et al. In-situ gelling system: a novel approach for ocular drug delivery
JP2016530321A5 (ja) イオン性液体を含有する注射用液状タンパク質製剤およびその使用
KR20140091707A (ko) 크실리톨로 안정화된 에타너셉트 제형
JP7223712B2 (ja) 安定なペプチド組成物
KR20190027878A (ko) 치료 단백질 제제용 안정화 부형제
CN104159614A (zh) TNF-α抗体的药物制剂
JP2019525951A5 (OSRAM)
US20160120946A1 (en) Compositions comprising gc-macrophage activating factor and uses thereof
WO2012012388A3 (en) Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
JP2019532949A (ja) 耐熱保護剤、室温で保存可能な豚コレラ生ワクチンの製造方法及びその使用
MX2015005230A (es) Composicion farmaceutica estable de peginterferon alfa-2b.
CN112656939B (zh) 一种针对血管内皮生长因子的人源化抗体的药物组合物
EP4003290B1 (en) Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances
JPWO2000000221A1 (ja) 水溶性乾燥組成物
CN105412942A (zh) 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂
US11229702B1 (en) High concentration formulations of adalimumab
CN115518151A (zh) 一种人类免疫缺陷病毒中和抗体制剂及其用途
CN101376022A (zh) 含聚乙二醇降纤酶的药物组合物
WO1999045953A1 (fr) Compositions contenant un cofacteur ii de l'heparine et techniques de stabilisation
CN110799188A (zh) 基于托品酰胺的眼用制剂
HK1175721A (en) Liquid formulations for long-acting g-csf conjugate
JPH07242562A (ja) 顆粒球コロニー刺激因子含有直腸投与製剤